ICTUImperial Clinical Trials Unit

Welcome to Imperial Clinical Trials Unit (ICTU)

This website is intended for commercial trial sponsors engaged in the area of pharmaceuticals, medical devices or diagnostic devices

Clinical Trials Search

OR

CurrentAll Trials

MOTION

Trial Details

  • Trial statusFollowup
  • Study email contactMOTION@imperial.ac.uk
  • Chief InvestigatorDr Parind Patel
  • Project managerAisha Anjum
  • SponsorImperial College Academic Health Science Centre
  • ISRCTN numberISRCTN75305839
  • PhaseIV

Methylnaltrexone for the Treatment of Opioid Induced Constipation & Gastro-Intestinal Stasis in Intensive Care Patients

Design and Objective

This is an interventional, double blind randomized, placebo controlled trial. It will be conducted at the 3 General Intensive Care Units within Imperial College Healthcare NHS Trust. The study will recruit 84 patients.

Key inclusion criteria

- Male/female ≥ 18 years of age - In ICU, sedated with opioids and on invasive ventilation - Requiring opioids for at least a further 24 hours - Constipated (not opened bowels for at least 48 hours in ICU) - On nasogastric tube feeds - Enteral access for administration of medications - Patient weight of 38-114kg

Study Disclaimer Statement